Last close As at 05/08/2026
GBP1.12
▲ −1.40 (−1.23%)
Market capitalisation
GBP698m
Research: Real Estate
Target Healthcare REIT’s mid-year rebasing of DPS sought to establish a base for growth on a fully covered basis. With FY23 results in line with previous indications, and progress continuing, the company has increased the quarterly rate of DPS by 2% from Q124. With rent collection restored, we expect rental growth, development completions and fixed debt costs to support continued, progressive, fully covered dividend growth.
Target Healthcare REIT |
DPS growth from a sustainable base |
FY23 results and outlook |
Real estate |
7 November 2023 |
Share price performance
Business description
Next events
Analyst
Target Healthcare REIT is a research client of Edison Investment Research Limited |
||||||||||||||||||||||||||||||||||||||||||||||||
Target Healthcare REIT’s mid-year rebasing of DPS sought to establish a base for growth on a fully covered basis. With FY23 results in line with previous indications, and progress continuing, the company has increased the quarterly rate of DPS by 2% from Q124. With rent collection restored, we expect rental growth, development completions and fixed debt costs to support continued, progressive, fully covered dividend growth.
Year end |
Rental |
Adjusted earnings* (£m) |
Adjusted |
NAV**/ |
DPS |
P/NAV |
Yield |
06/22 |
63.9 |
30.2 |
5.0 |
112.3 |
6.76 |
0.72 |
8.4 |
06/23 |
67.7 |
37.2 |
6.0 |
104.5 |
6.18 |
0.77 |
7.7 |
06/24e |
69.0 |
37.2 |
6.0 |
107.9 |
5.71 |
0.75 |
7.1 |
06/25e |
73.8 |
39.3 |
6.3 |
111.5 |
5.84 |
0.72 |
7.3 |
Note: *Adjusted earnings exclude revaluation movements, non-cash income arising from the accounting treatment of lease incentives and guaranteed rent review uplifts and acquisition costs, and include development interest under forward fund agreements. **NAV is net tangible assets (NTA) throughout this report.
Operational improvement driving confidence
As presaged by Q4 data, FY23 adjusted earnings per share grew strongly and NAV was robust, increasing through H2 as rents continued to increase and property yields stabilised. FY23 DPS of 6.18 was 97% covered, with the rebased H2 DPS of 2.8p (annualised 5.6p) covered 1.07x compared with H1 DPS of 3.38p, covered 0.89x. For Q124, DPS is increased 2% to 1.428p and the company targets similar quarterly payments through the year. This confidence reflects the improvement in rent collection (above 99% in Q124 vs the FY23 average of 97%), the result of active asset management and improved trading conditions for tenants. Fee growth and rising occupancy have offset inflationary cost pressures on tenants and rent cover has reached a new high level. FY24e adjusted earnings is slightly reduced but covers DPS 1.05x. For FY25, we expect further fully covered DPS growth. Debt costs are fixed at 3.7% until November 2025 and, based on current market interest rates, we expect DPS to be fully covered post refinancing.
Profitably meeting a social need
A growing elderly population and the need to improve the existing estate point to continuing demand for modern, high-quality, ESG-compliant residential facilities. With its unwavering focus on asset quality, these are the homes in which Target invests. Not only are they appealing to residents (two-thirds private pay), but they also support operators in providing better, more efficient and more effective care. When let at sustainable rent levels in well-located areas, with strong supply/demand characteristics, they will always be attractive to existing or alternative tenants and are key to providing sustainable, long-duration, inflation-linked income.
Valuation: Attractive yield with DPS growing again
The 5.71p FY24 DPS target represents an attractive yield of 7.1% and we expect further growth on a fully covered basis. Property values have recently stabilised, yet the discount to the Q124 NAV per share of 105.6p is 24%.
Report summary
FY23 results were in line with the indications reported with the Q423 report published in August and covered in our update note and progress has continued in Q124. This report begins with a detailed commentary on our expectations for further earnings and dividend growth and attractive total returns. For those less familiar with the company, later in this report we discuss Target’s strategy and portfolio and its investment focus on high-quality, modern, purpose-built properties. Of particular note:
■
Structural and demographic support underpins Target’s core proposition of generating long-term, sustainable, income-driven returns. Its focus on asset quality is central to this and strongly enhances the social impact that the company generates.
■
Effectively, all rents are inflation-linked (typically capped and collared between 2% and 4%) with a weighted average unexpired lease term (WAULT) of 26 years.
■
The resilience of tenant operators has been demonstrated through the pandemic and the subsequent spike in inflation. The demand for care home places is effectively non-discretionary and largely uncorrelated with the economy.
■
Where tenant issues arise, high-quality assets remain attractive to a wide range of alternative operators.
■
Healthcare property has traditionally generated superior risk-adjusted returns relative to the broad sector. The long-duration, visible inflation-linked income prospects for high-quality care home assets remain attractive to investors and are supporting property values.
■
With the dividend re-based to a level that better reflects an environment of higher interest rates and capital costs and interest costs fixed, we expect organic rental growth (and development completions) to drive growth in earnings and fully covered dividends.
We start the report by reviewing our updated forecasts.
Development completions and rent growth to drive earnings acceleration in FY25
With many of the key financial data previously disclosed in the unaudited Q423 update and reflected in our previous note, the FY23 financial performance provided no surprises. The changes to our FY24 adjusted earnings forecasts are modest and primarily related to an increased assumption for loan arrangement fee amortisation and debt facility non-utilisation fees. Our dividend forecast is in line with the company’s target, slightly below our previous assumption, and is 1.05x covered (1.33x on an EPRA basis). We have also introduced a new FY25 forecast, with earnings growth driven by rent reviews and development completions. We forecast further growth in FY25 DPS of a little over 2%, with cover increasing to 1.09x.
Exhibit 1: Forecast summary
New forecast |
Previous forecast |
Forecast change |
Forecast change |
|||||
£m unless stated otherwise |
FY24 |
FY25 |
FY24 |
FY25 |
FY24 |
FY25 |
FY24 |
FY25 |
Cash rental income |
58.1 |
62.6 |
58.8 |
N/A |
(0.6) |
N/A |
-1.1% |
58.1 |
Credit loss allowance |
(0.6) |
(0.6) |
(0.6) |
N/A |
0.0 |
N/A |
(0.6) |
|
Expenses |
(10.6) |
(10.9) |
(10.5) |
N/A |
(0.0) |
N/A |
0.2% |
(10.6) |
Net finance costs |
(10.6) |
(11.7) |
(10.0) |
N/A |
(0.7) |
N/A |
6.7% |
(10.6) |
Adjust for development interest under forward fund agreements |
0.8 |
0.0 |
0.7 |
N/A |
0.1 |
N/A |
17.7% |
0.8 |
Adjusted earnings |
37.2 |
39.3 |
38.4 |
N/A |
(1.2) |
N/A |
-3.2% |
37.2 |
Adjust for development interest under forward fund agreements |
(0.8) |
(0.0) |
(0.7) |
N/A |
(0.1) |
N/A |
(0.8) |
|
Non-cash IFRS adjustments |
10.8 |
11.2 |
10.9 |
N/A |
(0.1) |
N/A |
10.8 |
|
EPRA earnings |
47.2 |
50.5 |
48.6 |
N/A |
(1.4) |
N/A |
-2.9% |
47.2 |
EPRA EPS (p) |
7.6 |
8.1 |
7.8 |
N/A |
(0.2) |
N/A |
-2.9% |
7.6 |
Adjusted EPS (p) |
6.0 |
6.3 |
6.2 |
N/A |
(0.2) |
N/A |
-3.2% |
6.0 |
DPS declared (p) |
5.712 |
5.840 |
5.800 |
N/A |
(0.088) |
N/A |
-1.5% |
5.712 |
EPRA DPS cover (x) |
1.33 |
1.39 |
1.35 |
N/A |
N/A |
1.33 |
||
Adjusted DPS cover (x) |
1.05 |
1.09 |
1.07 |
N/A |
N/A |
1.05 |
||
EPRA NTA per share (NAV) (p) |
108 |
112 |
110.0 |
N/A |
(2.0) |
N/A |
-1.8% |
108 |
NAV total return |
8.8% |
8.7% |
10.8% |
N/A |
N/A |
8.8% |
||
Source: Target Healthcare REIT FY23 data, Edison Investment Research forecasts
Rental growth is the key to our forecasts, offsetting higher financing costs and expenses in FY24 to maintain earnings, and driving earnings growth in FY25.
Like-for-like rental growth should continue to benefit from annual, inflation-indexed rent reviews2, mostly collared and capped at 2% and 4% respectively.3 Annual fixed uplifts apply to 1% of rental income. Rent reviews added 3.8% pa to contractual rental income in both FY23 and FY22 and we forecast a similar rate of increase in FY24 and FY25. Independent forecasts provided to the UK treasury4 indicate that annual RPI inflation is unlikely to fall below 4% before the end of 2024 and the average rate of annualised inflation through the 12 months to 30 June 2025 (FY25) should remain above 4%. We expect this to add somewhat more than £2m pa to annualised contracted rents in each of FY25 and FY25.
1 Approximately 99% linked to the Retail Price Index (RPI) with the balance subject to fixed uplifts.
2 Collars represent the minimum level of annual rent uplift and caps the maximum, irrespective of the actual level of inflation.
3 HM Treasury – Forecasts for the UK economy: a comparison of independent forecasts, October 2023.
We forecast that the completion of forward-funded development projects (there are currently five under construction) will add an additional £4.0m to annual contracted rental income by end-FY25, well ahead of our estimate of the interest earned by Target in respect of the average funding extended for the construction costs during the build period.
Our forecasts for annualised contracted rent roll are shown in Exhibit 2 and, on a weighted basis, these are reflected in our rental income forecasts for FY24 and FY25. The contribution of the FY25 rent roll growth will not be fully reflected in the income statement until FY26.
Exhibit 2: Edison forecast development of annualised contracted rent roll
£m |
FY24 |
FY25 |
Start-year annualised contracted rent roll |
56.6 |
61.0 |
Rent reviews |
2.1 |
2.3 |
Acquisitions |
0.0 |
0.0 |
Disposals |
0.0 |
0.0 |
Development completions |
2.3 |
1.7 |
End-year annualised contracted rent roll |
61.0 |
65.0 |
Source: Edison Investment Research
We have estimated the rent roll contribution from development completions based on an assumed initial yield of 6% on the development cost including land, although actual yields are likely to differ from project to project according to factors such as the property specification and locality, as well as market pricing at the time of commitment. The assumed yield is similar to the current portfolio EPRA topped-up net initial yield of 6.22%.
Our forecasts for expenses are very much driven by investment management fees, lined directly to average net asset value. Other expenses increase with inflation. Credit loss provisions at a rate of 1% of rents are included in our forecasts, in line with current rent collection and acknowledging that a minority of tenants will inevitably encounter challenges from time to time.
Stabilising property yields
With underlying earnings substantially distributed, our NAV forecasts are driven by our property valuation assumptions.
Strong care sector fundamentals and non-cyclical, long-term, inflation-protected income prospects have mitigated the impact of rising bond yields and economic uncertainty on property values. In contrast to the broader sector, investment demand for good-quality care home properties, especially modern, purpose-built properties with strong environmental credentials, has remained robust. In the year to June 2023, Target’s property values fell 4.1% on a like-for-like basis compared with c 19% across the broad UK property sector. The FY23 valuation movement reflected c 40bp (0.4%) of yield widening (£73m valuation reduction), partly offset by rental growth (£36m valuation increase).5 All of the net decline came in H1, with rental growth yield stabilisation in H2 reflected in 1.5% like-for-like valuation growth. Despite continued volatility in the bond market, the portfolio yield was unchanged in Q124, with rental growth driving a 0.8% like-for-like portfolio gain. Nonetheless, our forecasts imply only a modest (c 15bp or 0.15%) widening over the forecast period. Each 10bp (0.1%) increase in this implied yield is equivalent to a 2.3p reduction in forecast NAV per share, with a broadly equivalent increase in NAV from a lower yield.
4 In aggregate, including the impact of acquisitions, disposals and development funding, the value of the investment portfolio declined by £43m.
Fee growth and occupancy improvements offset inflationary pressure on tenants
The operator sector, in general, is benefiting from increased occupancy, recovering from the pandemic, and strong fee growth, while a temporary relaxation of immigration rules for care workers is relieving some of the pressure on staffing, supporting the provision of care and reducing the cost of agency provision. In combination this has provided an effective offset to inflationary cost pressures.
Based on data gathered from its tenants, underlying resident occupancy in Target’s mature homes6 remains on a slow but consistently upward trajectory, to 85% at end-FY23 and 86% in Q124. During the pandemic, occupancy reached a low of c 74% in April 2021 and there is further room for growth until it reaches the c 90% level that was typical before the pandemic. Target says that many operators have been focused on admitting new residents at fee levels appropriate to the care package required, as opposed to prioritising occupancy in itself.
5 Homes that have had the same operator for a three-year period or more, and therefore excluding newly developed homes not yet stabilised.
Privately funded weekly fees have continued to outstrip inflation, as has been the case over the past 25 years, and data collected from the company’s tenants show 13% growth in average weekly fees charged to residents in the year to June 2023. Target says that in this inflationary environment, increased fees have generally been recognised as inevitable to support critical care needs. Over the longer term, average weekly fee growth has more than matched inflation The company has observed that recent local authority fee awards have been mixed and that there are pockets of poor fee awards where authorities lack the ability or willingness to match inflationary cost pressures. 68% of residents within Target-owned homes are funded privately, wholly or through fee top-ups, ahead of the market as a whole (we estimate c 50%, with the balance of fee growth publicly sourced).
From its tenant data, Target estimates that staff costs have increased c 6% in FY23, with wage growth mitigated by lower use of expensive agency staff. Not surprisingly, staffing is the largest single cost item for the sector, typically accounting for c 60% of revenues. Energy costs and other operational expenses, an aggregate 16% of costs within Target’s homes, remained stable. With rent increases typically capped at c 4%, it is easy to understand why rent cover7 is improving so strongly.
6 Rent cover is a key measure of the underlying profitability of tenants and the sustainability of rents. The ratio tracks operational cash earnings at the home level (before rent), or EBITDARM, with the agreed rent and is presented on a rolling 12-month basis.
Rent cover has continued to increase
Rent cover for mature homes,8 now 90% of the total, has continued to increase and was 1.75x in the June 2023 quarter compared with 1.47x in the prior year period. On a rolling 12-month basis, yet to fully reflect the continuing improvement, rent cover to end-June 2023 was 1.6x (12 months to June 2022: 1.3x).
7 A mature home is one that has been in operation for more than three years.
On a quarterly (or spot basis) basis, cover is now above its pre-pandemic level, when resident occupancy was higher, and is also above the 1.6x that Target has previously indicated to be a realistic medium-term target for a typical home. Nonetheless, with room for resident occupancy to increase further, there seems every prospect of rent cover continuing to build.
|
Exhibit 3: Rent cover turning upwards |
Exhibit 4: Increasing share of homes at maturity |
|
|
|
Source: Target Healthcare REIT |
Source: Target Healthcare REIT |
|
Exhibit 3: Rent cover turning upwards |
|
|
Source: Target Healthcare REIT |
|
Exhibit 4: Increasing share of homes at maturity |
|
|
Source: Target Healthcare REIT |
Rent collection back above 99%
Asset management initiatives and improved trading conditions have restored rent collection to in excess of 99% as of Q124, slightly above the end-FY23 level, having previously dipped to around 90% during FY22, with a small number of tenants slow to recover from the pandemic. Average rent collection throughout FY23 was 97%.
During Q123, Target reached a settlement with the operator of seven homes (c 6% of rent roll), which was only partly meeting its rent commitments. With the trading environment improving, the tenant renewed its long-term commitment to the homes and settled all rent in arrears, providing an immediate improvement in rent collection and generating a recovery in rent provisioning of £1.1m. As a result of this settlement alone, the run-rate of rent collection increased immediately to c 95% and in 2023 rents have been received in full.
Further progress on rent cover was achieved with the re-tenanting of one of the four Target homes it operated was completed in Q323 with the effect of alleviating cash flow pressures and allowing it to return to a fully rent-paying position on its three remaining homes. Existing lease terms, including rent levels, were maintained with the incoming tenant being granted a short-term rent-free period to manage the rebuild in occupancy.
While the improvement in trading conditions has benefited tenants across the portfolio, one tenant in particular, the operator of two Target homes, responsible for a significant proportion of the rent arrears, moved to full payment of rents in 2023 on the back of improved rent cover. To further support the tenant’s plans for its business and grow the returns on its assets, Target is investing £2.5m in one of the homes, creating an additional 18 rooms, soon to complete. During Q124, £1.7m of the costs were incurred and 10 of the rooms were completed. A portion of these will be immediately sub-let for three years by the operator to a local charitable organisation, at which point it is anticipated that the tenant will be able to take back the space for its own operation. Target’s rental income on the property will increase at a net initial yield consistent with the current property valuation and rent cover for the tenant is expected to improve. Post-completion, the tenant (including the sub-let) will represent 4.6% of the portfolio’s contracted rent. Previously provided for historical rent arrears will be partly written off, while rent deposits covering both properties operated by this tenant have been established to further strengthen the surety of rent receipts.
The acquisition of newly built homes has been an important element in building a high-quality portfolio and continues to be so (there are currently five properties under development). However, new homes take time to build occupancy and reach a ‘stabilised’ level of profitability, especially when targeting privately funded residents, a process that may take three years or more. As the pandemic hit, around 30% of Target’s portfolio was categorised as immature (compared with 10% now). The immature homes are a combination of the recently opened homes as well as a limited number of tenants which were also maturing as businesses and were not at a stage where they had built sufficient reserves to absorb a materially slower rate of occupancy growth.
Target’s ability to re-tenant properties, and in some cases sell them, is key to maintaining occupancy and income and this has been greatly facilitated by a focus on high-quality, modern and ESG-compliant assets that are attractive to residents, operators and investors. Its investment thesis is that best-in-class properties in local areas with positive demand/supply characteristics and prevailing rental levels that are sustainable will always be attractive to existing or alternative tenants.
Debt financing at fixed cost
Of Target’s £320m of debt facilities, £243m was drawn at end-Q124 (end-FY23: £230.0m), with an average term to maturity of 6.0 years. The drawn borrowing comprised £150m of long-term fixed rate debt at a low average cost of 3.2%, with a first maturity in 2032, and £93m of shorter-term debt. The shorter-term debt is floating rate but the interest costs on £80m of this have been capped at least until November 2025. In aggregate, 95% of the Q124 drawn debt was fixed/hedged at an all-in rate, including the amortisation of loan arrangement costs, of 3.91% (end-FY23: 3.70%).
The £77m of undrawn borrowing would, if fully drawn, be at a variable cost, including amortisation of loan arrangement fees, of 2.46% plus SONIA (or an interest cost before fees of 2.21%).
Allowing for capital commitments of c £35m, primarily in respect of funding for the five development assets, the company had available capital of £42m at end-Q124. Including the utilisation of cash balances, our forecasts assume an additional £25m of debt drawing, taking outstanding borrowings to £268m. Based on the hedging arrangements currently in place, this limits exposure to any further increase in interest rates before November 2025 to £38m of c 15% of projected borrowings. Meanwhile, the company has the flexibility to react to any decline in interest rates during this period.
Exhibit 5: Summary of debt financing (as at end-Q124)
Lender |
Facility type |
Facility |
Drawn |
Term |
Margin |
Hedging |
Phoenix/Reassure |
Term loan |
£50m |
£50m |
Jan-32 |
Fixed 3.28% |
N/A |
Phoenix/Reassure |
Term loan |
£37m |
£37m |
Jan-32 |
Fixed 3.13% |
N/A |
Phoenix/Reassure |
Term loan |
£63m |
£63m |
Jan-37 |
Fixed 3.14% |
N/A |
RBS |
Term loan |
£50m |
£30m |
Nov-25 |
SONIA + 2.18% |
£30m swapped at 0.3% |
Revolving credit facility |
£20m |
Nov-25 |
SONIA + 2.33% |
|||
HSBC |
Revolving credit facility |
£100m |
£63m |
Nov-25 |
SONIA + 2.17% |
£50m capped at 3.0% |
Source: Target Healthcare REIT
Market interest rate expectations remain volatile but, at the time of this report, do not indicate any further increase in the Bank of England base rate, closely tracked by the SONIA market rate, and currently 5.25% with a decline to c 4% by November 2025. This indicates an increase in borrowing costs, of shorter-term floating rate borrowings no later than the maturity in November 2025, corresponding with the expiry of the hedges. However, based on current market interest rates, we estimate that a good level of dividend cover would remain.
Assuming the shorter-term borrowing were to be refinanced at a SONIA rate of 4.0% plus a lending margin of 2.5% (6.5% in aggregate), the impact would be to increase the overall blended all-in cost of borrowing to 4.9%, or an annualised £13.0m. This represents an increase of c £2.5m9 compared with our existing forecast for the 12 months to 30 June 2025 (FY25). If applied to that FY25 forecast on an annualised basis, dividend cover would be c 1.02x, before the further contracted rent growth in FY26.
8 The £12.5m FY25 net finance cost shown in the financial summary table at the back of this report includes £10.5m of interest on loans, £1.2m of loan fee amortisation and facility non-utilisation fees. It also includes c £0.8m amortisation of the interest rate derivatives, excluded from adjusted earnings.
Exhibit 6: Illustrated impact on debt cost of refinancing shorter-term debt at 6.5%
Borrowings (£m) |
Cost (%) |
Cost (£m) |
|
Long-term fixed rate debt |
150 |
3.2% |
4.8 |
Other debt |
118 |
6.5% |
7.7 |
Total debt |
268 |
4.6% |
12.4 |
Amortisation of loan fees |
0.6 |
||
All-in cost |
268 |
4.9% |
13.0 |
Source: Edison Investment Research
Allowing for cash, the end-Q124 loan to value ratio was 25.0% (end-FY23: 24.7%). On a pro forma basis, adjusting for outstanding capital commitments, the Q124 LTV was c 28%.
Each loan facility is secured against a discrete pool of assets with specific loan covenants. These include maximum loan to value ratios of at 40–50% and minimum interest cover ratios of 200–225%. Target is well within these requirements and at end-FY23 had unencumbered assets with a value of c £107m.
Income-driven returns
Target is primarily focused on income returns, and progressively increased DPS in the period from listing to H123. The re-basing in mid-FY23 (from a quarterly rate of 1.690p to 1.400p) was in recognition of the change in market conditions, to a level from which it could continue to grow on a sustainable basis. The increase in the Q124 DPS to 1.42p (+2%), which the company intends to maintain throughout FY24, suggests this is the case. We forecast aggregate FY24 DPS of 5.71p, 1.05x covered by adjusted earnings, with further 2.2% growth in FY25, 1.09x covered. This would leave Target in a strong position to maintain dividend progression through FY26 despite the maturity of interest rate hedging.
Exhibit 7: Quarterly dividend development
Pence/share |
FY22 |
FY23 |
FY23/FY22 |
FY24e |
FY24e/FY23 |
FY25e |
FY25e/FY24e |
Q1 |
1.690 |
1.690 |
0.0% |
1.428 |
-15.5% |
1.460 |
2.2% |
Q2 |
1.690 |
1.690 |
0.0% |
1.428 |
-15.5% |
1.460 |
2.2% |
Q3 |
1.690 |
1.400 |
-17.2% |
1.428 |
2.0% |
1.460 |
2.2% |
Q4 |
1.690 |
1.400 |
-17.2% |
1.428 |
2.0% |
1.460 |
2.2% |
Full year |
6.760 |
6.180 |
-8.6% |
5.712 |
-7.6% |
5.840 |
2.2% |
Source: Target Healthcare REIT historical data, Edison Investment Research FY24 and FY25 forecasts
Historically, the company has aimed for DPS to be fully covered by adjusted earnings, assuming full deployment of available capital. Adjusted earnings provide a better indication of dividend capacity than EPRA earnings, which include significant non-cash IFRS rent smoothing adjustments.10 However, with consistent growth in both the capital base and the portfolio, the earnings reported in any period have historically always been in a process of catch-up to the fully invested potential, with dividends less than fully covered. However, the sharp rise in interest rates, well in excess of the widening in acquisition yields, has significantly removed the opportunity for accretive acquisitions, delaying the expected path to full dividend cover. Uncovered dividends also require additional borrowing, which is unattractive at higher borrowing rates. It was against this background that the board decided it was appropriate to rebase dividends, despite the improvement in tenant performance and rent collection.
9 The recognition of future contractual rent uplifts, which IFRS requires to be recognised on a straight-line basis.
Looking beyond our forecast period, we expect the company to align dividends more closely with immediate earnings.
|
Exhibit 8: Dividend growth and cover |
|
|
Source: Target Healthcare REIT data, Edison Investment Research. Note: We have taken the data from the first 12-month period following listing. Dividends of 6.5p were declared and paid for the c 15-month period from listing in March 2013 to 30 June 2014. |
Dividends have generated 90% of total return since listing
Since listing in March 2013, up to end-Q124, the aggregate NAV/accounting total return (not including reinvestment of dividends paid)11 is 75% or an average 5.4% pa. Dividends paid have accounted for 90% of returns. Capital returns have mostly been positive until H123 (June to December 2022) when property values declined in common with the broad commercial property sector. With its property values beginning to recover in H223, the total return of 4.5% substantially offset the H123 negative return of 5.2%, Overall, FY23 total return was overall negative (1.2%), the only year since listing. This positive trend continued in Q124, with a total return of 2.4%.
10 The average annual return to end-FY23 was also 5.4% pa excluding reinvestment of dividends. Target calculates that including reinvestment, the average annual return over the same period was 6.9%.
Exhibit 9: NAV total return history and Edison forecast
Pence/share unless stated otherwise |
FY14* |
FY15 |
FY16 |
FY17 |
FY18 |
FY19 |
FY20 |
FY21 |
FY22 |
FY23 |
Q124 |
FY14-Q124 |
FY24e |
FY25e |
Opening NAV |
98.0 |
94.7 |
97.9 |
100.6 |
101.9 |
105.7 |
107.5 |
108.1 |
110.4 |
112.3 |
104.5 |
98.0 |
104.5 |
107.9 |
Closing NAV |
94.7 |
97.9 |
100.6 |
101.9 |
105.7 |
107.5 |
108.1 |
110.4 |
112.3 |
104.5 |
105.6 |
105.6 |
107.9 |
111.5 |
DPS paid |
6.5 |
6.1 |
6.2 |
6.3 |
6.4 |
6.5 |
6.7 |
6.7 |
6.8 |
6.5 |
1.4 |
65.9 |
5.7 |
5.8 |
Dividend return |
6.6% |
6.4% |
6.3% |
6.2% |
6.3% |
6.2% |
6.2% |
6.2% |
6.1% |
5.8% |
1.3% |
67.3% |
5.4% |
5.4% |
Capital return |
-3.3% |
3.3% |
2.7% |
1.3% |
3.8% |
1.6% |
0.6% |
2.2% |
1.7% |
-7.0% |
1.1% |
7.8% |
3.3% |
3.3% |
NAV total return |
3.3% |
9.7% |
9.0% |
7.5% |
10.1% |
7.8% |
6.8% |
8.4% |
7.8% |
-1.2% |
2.4% |
75.0% |
8.8% |
8.7% |
Average total return pa |
5.4% |
Source: Target Healthcare data, Edison Investment Research. Note: *22 January 2013 to 30 June 2014. Opening NAV adjusted for IPO costs.
FY23 financial results
The table below provides a summary of FY23 financial performance, starting with adjusted earnings before reconciling these to both EPRA earnings and the statutory reported IFRS earnings.
Exhibit 10: Summary of FY23 financial performance
£m unless stated otherwise |
FY23 |
FY22 |
FY23/FY22 |
H123 |
H1223 |
Rental income excluding guaranteed uplifts |
56.4 |
48.8 |
15% |
28.1 |
28.3 |
Other income |
0.1 |
1.0 |
0.1 |
0.0 |
|
Credit loss allowance |
(0.3) |
(3.2) |
-92% |
0.0 |
(0.3) |
Investment management fees |
(7.4) |
(7.3) |
2% |
(3.8) |
(3.6) |
Other expenses |
(3.0) |
(3.2) |
-4% |
(1.6) |
(1.5) |
Finance expense |
(9.4) |
(6.6) |
43% |
(4.6) |
(4.9) |
Development interest under forward fund agreements |
1.0 |
0.8 |
22% |
0.5 |
0.5 |
Adjusted earnings |
37.2 |
30.2 |
23% |
18.7 |
18.5 |
Development interest under forward fund agreements |
(1.0) |
(0.8) |
(0.5) |
(0.5) |
|
Income from guaranteed rent reviews & lease incentives |
11.3 |
10.2 |
5.9 |
5.4 |
|
EPRA earnings |
47.6 |
39.7 |
20% |
24.1 |
23.4 |
Realised/unrealised gains/(losses) on properties |
(53.4) |
5.5 |
(58.0) |
4.6 |
|
Interest rate cap |
(0.7) |
0.0 |
(0.3) |
(0.4) |
|
Other income |
3.9 |
0.0 |
1.0 |
||
IFRS earnings |
(6.6) |
49.1 |
-113% |
(34.2) |
27.6 |
IFRS EPS (p) |
(1.06) |
8.20 |
-113% |
(5.51) |
4.45 |
EPRA EPS (p) |
7.67 |
6.62 |
16% |
3.89 |
3.78 |
Adjusted EPS (p) |
6.00 |
5.05 |
19% |
3.01 |
2.99 |
DPS declared (p) |
6.18 |
6.76 |
-9% |
3.38 |
2.80 |
Dividend cover - EPRA earnings (x) |
1.24 |
0.95 |
0.00 |
0.00 |
|
Dividend cover - Adjusted earnings (x) |
0.97 |
0.72 |
0.89 |
1.07 |
|
EPRA NTA per share (p) |
104.5 |
112.3 |
103.0 |
104.5 |
|
EPRA NTA total return/accounting total return |
-1.2% |
7.8% |
-5.2% |
4.4% |
|
Investment properties including investment via loans |
868.7 |
911.6 |
867.7 |
868.7 |
|
Borrowings |
230.0 |
234.8 |
240.0 |
230.0 |
|
Cash |
15.4 |
34.5 |
21.8 |
15.4 |
|
Gross LTV |
26.5% |
25.8% |
27.7% |
26.5% |
|
Net LTV |
24.7% |
22.0% |
25.1% |
24.7% |
Source: Target Healthcare REIT data
In respect of adjusted earnings, in particular we highlight:
■
Strong growth in rental income excluding non-cash IFRS adjustments for guaranteed rental uplifts. The impact of the five properties disposed of during the year was more than offset by a full year contribution from significant portfolio of properties acquired id-way through the prior year as well as indexed rent uplifts.
■
A much-reduced credit loss allowance, reflecting the underlying recovery in rent collection through the year.
■
Investment management fees, linked to average net assets, increased only modestly while other costs were tightly controlled and declined modestly. The adjusted EPRA cost ratio (excluding the impact of guaranteed rental uplifts) was reduced to 18.7% from 27.1% in FY22. Excluding credit loss provisions, it was also lower, at 15.5% versus 16.4%.
■
Adjusted finance expenses, which excludes amortisation of interest rate derivatives, increased to £9.4m from £6.6m in FY22, driven by an increase in the average value of drawn debt in FY23 (drawn debt increased by c £100m during FY22) as well as higher interest rates.
■
Including £1.0m of development interest accrued on forward fund agreements, adjusted earnings increased 23% or £7.0m to £37.2m and adjusted EPS by 19% to 6.0p.
■
DPS declared in the year was 6.18p, 0.97x covered by adjusted earnings. This comprised a H1 DPS of 3.38p, 0.89x covered, and a rebased 2.80p in H2, 1.07x covered.
■
EPRA earnings includes the non-cash IFRS adjustment for guaranteed rental uplifts but excludes development interest. EPRA earnings increased 20% to £47.6m with EPRA EPS per share of 7.67p. EPRA dividend cover was 1.24x.
■
IFRS earnings further included £53.4m of realised (£0.6m) and unrealised revaluation movements and the £0.7m amortisation of interest rate derivatives.
■
Not shown in the table above, IFRS net asset value per share was 105.6p and, adjusted for the fair value of interest rate derivatives, EPRA NTA per share was 104.5p.
Dividend yield remains attractive despite the rebasing
The targeted FY24 DPS of 5.712p represents a prospective yield of 7.1%, while the shares continue to trade at a discount to NAV of more than 20% despite property values recently increasing.
|
Exhibit 11: Dividend yield remains attractively high despite dividend rebasing |
Exhibit 12: P/NAV appears to discount material further property yield widening (valuation decline) |
|
|
|
Source: Target Healthcare REIT DPS data, Refinitiv prices |
Source: Target Healthcare REIT NAV per share data, Refinitiv prices |
|
Exhibit 11: Dividend yield remains attractively high despite dividend rebasing |
|
|
Source: Target Healthcare REIT DPS data, Refinitiv prices |
|
Exhibit 12: P/NAV appears to discount material further property yield widening (valuation decline) |
|
|
Source: Target Healthcare REIT NAV per share data, Refinitiv prices |
In Exhibit 13, we summarise the performance and valuation of a group of real estate investment trusts that we consider to be Target’s closest peers in the broad and diverse commercial property sector. The peer group is invested in the primary healthcare, supported housing and care home sectors, all targeting stable, long-term income growth derived from long lease exposures. For consistency, the data are presented on a trailing basis.
Target’s yield is below the average, although this is slightly inflated by Triple Point Social Housing’s (SOHO) high yield. Target’s P/NAV is broadly in line with the group, excluding SOHO.
Exhibit 13: Peer valuation and performance summary
WAULT* |
Price |
Market cap (£m) |
P/NAV** |
Yield*** |
Share price performance |
||||
One month |
Three months |
One year |
Three years |
||||||
Assura |
11 |
43 |
1291 |
0.81 |
7.3 |
4% |
-7% |
-23% |
-43% |
Impact Healthcare |
20 |
88 |
363 |
0.76 |
7.7 |
8% |
-3% |
-17% |
-15% |
Primary Health Properties |
11 |
96 |
1284 |
0.86 |
6.9 |
5% |
1% |
-16% |
-36% |
Residential Secure Income |
N/A |
60 |
111 |
0.68 |
8.6 |
0% |
-3% |
-33% |
-33% |
Triple Point Social Housing |
25 |
57 |
224 |
0.51 |
7.2 |
18% |
-10% |
-16% |
-49% |
Average |
17 |
0.73 |
7.5 |
7% |
-4% |
-21% |
-35% |
||
Target Healthcare |
26 |
81 |
499 |
0.76 |
7.1 |
5% |
11% |
-8% |
-28% |
UK property sector index |
1,210 |
4% |
-3% |
-9% |
-17% |
||||
UK equity market index |
4,021 |
-1% |
-2% |
1% |
21% |
||||
Source: company data, Refinitiv pricing at 3 November 2023. Note: *Weighted average unexpired lease term. **Based on last reported NAV/NTA. ***Based on trailing 12-month DPS declared.
Portfolio and strategy
Target operates in a structurally supported sector
The demand for care home spaces in the UK is expected to grow strongly. The number of people aged 85 or over is forecast to almost double over the next 25 years,12 with increasingly complex care needs. The numbers living with dementia are forecast to grow from an expected 1.0 million in 2024 to 1.6 million by 2040. The sector provides a substantially non-discretionary, essential service largely independent of the wider economy.
11 Office of National Statistics (ONS)
The number of care and nursing beds available has shown no material growth over the past 10 years, with newly developed and refurbished stock offset by the withdrawal of older, obsolete homes. Significant investment in the care home estate is required to meet existing and future needs and satisfy the expectations of residents and their families, as well as regulatory demands for better quality care.
Healthcare real estate has historically provided attractive risk-adjusted returns compared with the broader commercial real estate sector. Target’s portfolio has also continued to outperform the MSCI UK Annual Healthcare Property Index. In the year to December 2022, Target’s portfolio delivered a total return of 2.5% versus 1.7% for the index. Since Target was launched, its portfolio has returned 10.2% pa versus 6.9% for the index (and over five years, 8.6% versus 8.1
Sustainable assets
At the core of its strategy, Target has an unwavering focus on high-quality, modern and sustainable assets, attractive to residents, operators and investors. Its investment thesis is that best-in-class properties in local areas with positive demand/supply characteristics and prevailing rental levels that are sustainable will always be attractive to existing or alternative tenants.
Key portfolio metrics include:
■
80% of its homes have been purpose-built from 2010 onwards.
■
98% of Target’s rooms benefit from full ensuite wet room provision compared with 31% of total care home places in the UK, up from 14% in 2014. Capital expenditure projects are under way to increase portfolio wet room provision to 100%.
■
On average, homes provide 47sqm per resident including generous communal areas.
■
94% of the portfolio is EPC rated A or B and is compliant with the minimum energy efficiency standards anticipated to apply from 2030. 100% are rated C or better, already compliant with the minimum guidelines anticipated for 2027.
Further portfolio detail
At end-Q124, including the Weston-super-Mare development acquired in the period, Target’s portfolio comprised 98 homes, of which 93 were operational and five were development properties under construction. It was externally valued at £890.3m with annualised contracted rents of £57.1m, reflected in an EPRA topped-up net initial yield of 6.22%. Allowing for short-term lease incentives, annualised passing rent was £55.6m and the EPRA net initial yield was 6.05%. Contracted rents on the development properties are not included in these figures until completion. The WAULT was 26.3 years.
The homes are well diversified by geography and by tenant. Of the 32 tenants, the 10 largest account for 63% of contracted rent, with the largest individual tenant 16%. Of the 22 remaining tenants, each account for less than 3.3%.
Exhibit 14: Portfolio summary
Sep-23 |
Jun-23 |
Jun-22 |
|
Q124 |
FY23 |
FY22 |
|
Properties |
98 |
97 |
101 |
– of which completed |
3 |
93 |
97 |
– of which under development |
5 |
4 |
4 |
Beds |
6,508 |
6,442 |
6,703 |
Tenants |
32 |
32 |
34 |
Contracted rent (£m) |
57.1 |
56.6 |
55.5 |
Portfolio value (£m) |
890.3 |
868.7 |
911.6 |
WAULT |
26.3 years |
26.5 years |
27.2 years |
EPRA topped-up net initial yield |
6.22% |
6.22% |
5.82% |
Source: Target Healthcare REIT data
Completed forward-funded developments and the five that were under construction account for 21 of the portfolio assets. They provide access to attractive new homes that satisfy Target’s strict investment criteria that may be otherwise unavailable. They also bring much needed new capacity to the market. Target is itself not a developer and we believe that forward-funding developments is relatively low risk. Target acquires land plots, with planning consent, from developers and funds the construction, on fixed-price contracts, of pre-let homes. During the construction phase, Target accrues interest on the funding that has been extended and this is reflected as a deduction in the acquisition price. The interest is included in adjusted earnings.
During FY23, five properties were sold for an aggregate £25.8m after costs, all at above book value, realising a gain of £0.5m, and reducing annualised contracted rents by £2.1m. One of the properties had been acquired as part of the 18-home portfolio acquisition in December 2021 (H122), which added £9.3m to contracted rents at that time. Target says this property was below the average standard of the portfolio as a whole. Target also exited the Northern Irish market, where it says that the fee and resident funding dynamic is less favourable. The four homes sold in Northern Ireland represented c 2.5% of the overall portfolio value at the time (or c £22m).
The proceeds can be recycled into the new (and existing) developments on a gradual basis as construction proceeds over the next year or so. At the start of FY23, there were four homes under development of which one reached practical completion13 during the year. An additional home was acquired during FY23 and a further one in Q124.
12 The point at which construction is effectively complete and capable of occupation resuming.
■
In November 2022, practical completion was reached on a 66-bed home in Weymouth, leased to a new tenant to the group on a 35-year lease incorporating green provisions and annual rent reviews (subject to caps and collars).
■
In Q323, the acquisition of a development site near Malvern, Worcestershire, for the construction of a 60-bed home, pre-let to an existing tenant of the group on a 35-year lease incorporating green provisions and annual rent reviews (subject to caps and collars). Construction has commenced and is expected to reach practical completion in summer 2024.
■
In Q124, the acquisition of a development site in Weston-super-Mare, for the construction of a 66-bed home, pre-let to a new tenant on a 35-year lease incorporating green provisions and annual rent reviews (subject to caps and collars). The maximum commitment is £16.0m. Construction has commenced and is expected to reach practical completion in the summer of 2024.
The other three developments that are under construction are:
■
A 66-bed home at Olney, Buckinghamshire, acquired in June 2021. We assume practical completion by end-Q324.
■
A 66-bed home at Holt, Norfolk, acquired in August 2021. We assume practical completion by end-H124.
■
A 71-bed home at Dartford, Kent, acquired in April 2022. We assume practical completion by end-Q324
At end-FY23, there was £31.1m of capital committed to the completion of forward funding projects. Including the commitment to Weston-super-Mare and subsequent development funding we estimate this was little changed at end-Q124.
Target also invested £6.1m in FY23 in portfolio improvements, converting 128 beds into full wet rooms at four homes, increasing the proportion of portfolio beds to 98% from 96%, and commenced work on the addition of 18 rooms to another, discussed above. Ten of these homes were completed in Q124. A further £3.7m had been committed towards increasing the proportion of beds with wet rooms to 100%, with 15 upgrades completed in Q124. A portion of capital has also been allocated to direct carbon reduction initiatives, most notably the installation of photovoltaic panels, in partnership with tenants.
These organic investment projects are reflected in uplifts to contracted rents, reflecting net initial yields in line with market levels. This added 0.3% to the 1.0% increase in Q124 contracted rents, including rentalisation of the £1.7m cost of the 10-room addition to one home and £0.5m of wet room installation at another.
Management and governance
Independent board and specialist external manager
There have been several recent changes to Target’s independent non-executive board as part of its now completed succession planning. Alison Fyfe became chair in December 2022, having joined the board in May 2020 on the retirement of Malcolm Naish, who had held the position since the company listed in 2013. Ms Fyfe is an experienced property professional with 35 years’ experience in surveying, banking and property finance. She also has board experience, having acted as a director of a number of companies in the property and debt finance sector. The other directors of the company bring broad financial, commercial, property, fund management and healthcare experience. They are Dr Amanda Thompsell (appointed in February 2022), Richard Cotton (senior independent director, appointed in November 2022), Michael Brodtman (appointed in January 2023) and Vince Niblett (chair of the audit committee, appointed in August 2021).
Full details of board members can be found on the company’s website.
Externally managed by Target Fund Managers
Target Fund Managers (the investment manager) is a family-owned sector specialist manager investing exclusively in the elderly healthcare property sector. It is led by Kenneth MacKenzie, its chief executive, supported by a growing team of professionals, the core of which, including original co-founders John Flannelly and Andrew Brown, has worked closely together since 2010, providing continuity as well experience. This experience spans all aspects of the healthcare property sector, including operating, owning, investing in, developing and building healthcare businesses and healthcare property assets. We provide biographies of the key members involved in the management of Target Healthcare REIT on page 17.
The investment management fee schedule has a tiered fee structure with reducing rates at higher NAV levels, allowing shareholders to benefit from the increasing economies of scale that a larger portfolio provides. With end-FY23 net assets of £655m, the marginal investment management fee is 0.95%.
Exhibit 15: Management fee structure
Average net assets |
Fee margin |
First £500m |
1.05% |
£500m to £750m |
0.95% |
£750m to £1,000m |
0.85% |
£1,000m to £1,500m |
0.75% |
£1,500m+ |
0.65% |
Source: Target Healthcare REIT. Note: Rates effective 1 July 2018.
Sensitivities
The visibility of Target’s contractual income and dividend-paying capacity is provided by long leases and RPI-linked rent increases. We see the key sensitivities as relating to the following:
■
Regulatory changes or changes to government care policy have the potential to materially affect the sector, both positively and negatively, in ways that are difficult to predict. Significant reform of care sector funding has again been deferred.
■
While Target has no direct exposure to the operational and financial performance of the homes operated by its tenants, underperformance from time to time has a negative effect on the collection of contractual income. Active asset management and the appeal of its high-quality homes to alternative tenants provides protection.
■
Key operational and financial risks to the tenant operators include their ability to maintain high standards of care and compliance with stringent and evolving regulatory oversight, manage staff shortages, maintain good levels of occupancy and mitigate cost inflation with fee increases.
■
Average care home fees have risen at a faster rate than RPI in recent years, particularly fees for self-funded residents. In many cases, these fees will be met by a draw-down of home equity and/or other savings. Any sustained reduction in personal wealth could have a negative impact on the growth of privately funded fees.
■
Property values may be affected by further change in the cost of capital, investment demand for care home properties of the specification that Target focuses on, or tenant performance.
■
Of Target’s £320m of committed borrowing facilities, £170m (of which £83m is drawn) matures in November 2025 and must be refinanced. We fully expect Target to have ample access to new borrowings, although for now the cost of the refinanced debt is uncertain as the existing hedges expire.
■
As an externally managed REIT, Target is dependent on the investment manager’s ability, the retention of key staff and the ability to deliver business continuity.
Exhibit 16: Financial summary
Year to 30 June (£m) |
2021 |
2022 |
2023 |
2024e |
2025e |
INCOME STATEMENT |
|||||
Rental income excluding guaranteed uplift |
41.2 |
48.8 |
56.4 |
58.1 |
62.6 |
IFRS adjustment for guaranteed uplifts |
8.7 |
10.2 |
11.3 |
10.8 |
11.2 |
Other income |
0.1 |
4.8 |
0.1 |
0.0 |
0.0 |
Total revenue |
50.0 |
63.9 |
67.7 |
69.0 |
73.8 |
Gains/(losses) on revaluation |
9.4 |
5.5 |
(53.4) |
9.7 |
7.7 |
Realised gains/(losses) on disposal |
1.3 |
0.0 |
0.0 |
0.0 |
0.0 |
Management fee |
(5.8) |
(7.3) |
(7.4) |
(7.4) |
(7.6) |
Credit loss allowance & bad debts |
(2.7) |
(3.2) |
(0.3) |
(0.6) |
(0.6) |
Other expenses |
(2.6) |
(3.2) |
(3.0) |
(3.2) |
(3.4) |
Operating profit |
49.6 |
55.7 |
3.6 |
67.5 |
69.9 |
Net finance cost |
(5.7) |
(6.6) |
(10.1) |
(11.4) |
(12.5) |
IFRS net result |
43.9 |
49.1 |
(6.6) |
56.1 |
57.4 |
Adjust for: |
|||||
Gains/(losses) on revaluation |
(9.5) |
(5.6) |
54.0 |
(9.7) |
(7.7) |
Other EPRA adjustments |
(0.3) |
(3.9) |
0.1 |
0.8 |
0.8 |
EPRA earnings |
34.0 |
39.7 |
47.6 |
47.2 |
50.5 |
Adjust for fixed/guaranteed rent reviews |
(8.7) |
(10.2) |
(11.3) |
(10.8) |
(11.2) |
Adjust for development interest under forward fund agreements |
0.6 |
0.8 |
1.0 |
0.8 |
0.0 |
Group adjusted earnings |
26.0 |
30.2 |
37.2 |
37.2 |
39.3 |
Average number of shares in issue (m) |
475.4 |
599.1 |
620.2 |
620.2 |
620.2 |
IFRS EPS (p) |
9.23 |
8.20 |
(1.06) |
9.04 |
9.25 |
EPRA EPS (p) |
7.2 |
6.6 |
7.7 |
7.6 |
8.1 |
Adjusted EPS (p) |
5.5 |
5.0 |
6.0 |
6.0 |
6.3 |
Dividend per share (declared) |
6.72 |
6.76 |
6.18 |
5.71 |
5.84 |
Dividend cover (EPRA earnings) |
1.05 |
0.95 |
1.24 |
1.33 |
1.39 |
Dividend cover (adjusted earnings) |
0.80 |
0.72 |
0.97 |
1.05 |
1.09 |
BALANCE SHEET |
|||||
Investment properties |
631.2 |
857.7 |
800.2 |
852.0 |
867.4 |
Other non-current assets |
54.8 |
65.9 |
83.3 |
93.3 |
103.7 |
Non-current assets |
686.0 |
923.6 |
883.4 |
945.3 |
971.1 |
Cash and equivalents |
21.1 |
34.5 |
15.4 |
12.7 |
14.9 |
Other current assets |
11.3 |
5.5 |
9.5 |
5.3 |
5.6 |
Current assets |
32.4 |
40.0 |
24.8 |
18.0 |
20.6 |
Bank loan |
(127.9) |
(231.4) |
(227.1) |
(260.7) |
(266.3) |
Other non-current liabilities |
(6.8) |
(7.1) |
(8.1) |
(8.1) |
(8.1) |
Non-current liabilities |
(134.7) |
(238.5) |
(235.1) |
(268.8) |
(274.4) |
Trade and other payables |
(18.5) |
(26.4) |
(18.3) |
(18.9) |
(20.3) |
Current Liabilities |
(18.5) |
(26.4) |
(18.3) |
(18.9) |
(20.3) |
Net assets |
565.2 |
698.8 |
654.8 |
675.6 |
697.0 |
Adjust for derivative financial liability |
(0.3) |
(2.3) |
(6.9) |
(6.1) |
(5.3) |
EPRA net assets |
564.9 |
696.5 |
647.9 |
669.5 |
691.7 |
Period end shares (m) |
511.5 |
620.2 |
620.2 |
620.2 |
620.2 |
IFRS NAV per share (p) |
110.5 |
112.7 |
105.6 |
108.9 |
112.4 |
EPRA NTA per share (p) |
110.4 |
112.3 |
104.5 |
107.9 |
111.5 |
EPRA NTA total return |
8.4% |
7.8% |
-1.2% |
8.8% |
8.7% |
CASH FLOW |
|||||
Cash flow from operations |
29.2 |
35.6 |
40.8 |
51.8 |
52.0 |
Premium paid for interest rate cap |
(2.6) |
0.0 |
0.0 |
||
Net interest paid |
(4.2) |
(5.2) |
(8.6) |
(10.0) |
(11.1) |
Tax paid |
(0.0) |
(0.0) |
0.0 |
0.0 |
0.0 |
Net cash flow from operating activities |
25.0 |
30.4 |
29.7 |
41.8 |
40.9 |
Purchase of investment properties |
(51.4) |
(207.0) |
(29.3) |
(42.2) |
(7.7) |
Disposal of investment properties |
7.8 |
4.4 |
25.8 |
0.0 |
0.0 |
Net cash flow from investing activities |
(43.6) |
(202.6) |
(3.6) |
(42.2) |
(7.7) |
Issue of ordinary share capital (net of expenses) |
58.3 |
122.5 |
0.0 |
0.0 |
0.0 |
(Repayment)/drawdown of loans |
(22.0) |
104.8 |
(4.8) |
33.0 |
5.0 |
Dividends paid |
(31.5) |
(39.8) |
(40.3) |
(35.3) |
(36.0) |
Other |
(1.5) |
(1.8) |
(0.2) |
0.0 |
0.0 |
Net cash flow from financing activities |
3.3 |
185.6 |
(45.2) |
(2.3) |
(31.0) |
Net change in cash and equivalents |
(15.3) |
13.4 |
(19.1) |
(2.6) |
2.2 |
Opening cash and equivalents |
36.4 |
21.1 |
34.5 |
15.4 |
12.7 |
Closing cash and equivalents |
21.1 |
34.5 |
15.4 |
12.7 |
14.9 |
Balance sheet debt |
(127.9) |
(231.4) |
(227.1) |
(260.7) |
(266.3) |
Unamortised loan arrangement costs |
(2.1) |
(3.4) |
(2.9) |
(2.3) |
(1.7) |
Drawn debt |
(130.0) |
(234.8) |
(230.0) |
(263.0) |
(268.0) |
Net cash/(debt) |
(108.9) |
(200.3) |
(214.6) |
(250.3) |
(253.1) |
Gross LTV |
19.2% |
25.8% |
26.5% |
28.2% |
28.0% |
Net LTV |
16.1% |
22.0% |
24.7% |
26.9% |
26.4% |
Source: Target Healthcare REIT historical data, Edison Investment Research forecasts
|
|||||||||||||||||||||||||||||||||||||||||||||||
|
|
Research: TMT
Datatec reported a strong performance in H124, with revenue up 15% y-o-y, adjusted EBITDA up 2% and underlying EPS up 336%. As supply chain issues have eased, the company has been able to reduce its backlog from previously elevated levels. Datatec expects improved performance in all divisions in FY24. While the company closely manages working capital, higher revenues and a gradual reduction in supplier extended payment terms drive our higher net debt forecasts. Our estimates are broadly unchanged at a group level, with adjustments at a divisional level to reflect Westcon strength and uncertainty in Latin America, and higher operating profitability offsetting increased interest costs.